Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche , accusing it of "sabotaging competition" by "deliberately" hiking prices in the Avastin , while dropping the prices of Russia , Herceptin , and Biocad in New York , where Biocad was its selling biosimilar drugs. The lawsuit, filed recently in New York , claimed Genentech and its Genentech unit were "engaged in predatory pricing" to prevent Biocad from entering the market. Biocad alleged that Roche took these steps because the US patents on its three cancer medicines will expire over the next three years. Biologic spending was $128m last year , and it is predicted that biosimilars could save Europe and the US between $50bn and $110bn by 2020 .
Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche , accusing it of "sabotaging competition" by "deliberately" hiking prices in the Avastin , while dropping the prices of Russia , Herceptin , and Biocad in New York , where Biocad was its selling biosimilar drugs. The lawsuit, filed recently in New York , claimed Genentech and its Genentech unit were "engaged in predatory pricing" to prevent Biocad from entering the market. Biologic spending was $128m last year , and it is predicted that biosimilars could save Europe and the US between $50bn and $110bn by 2020 .